Inhibitor Therapeutics (OTCMKTS:INTI) Posts Quarterly Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) released its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Performance

INTI traded up $0.00 during trading on Friday, reaching $0.06. 147,145 shares of the company traded hands, compared to its average volume of 40,416. The company has a market cap of $10.34 million, a P/E ratio of -6.00 and a beta of -0.55. The firm has a fifty day simple moving average of $0.06 and a 200 day simple moving average of $0.07. Inhibitor Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.14.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.